Global Chronic Disease Management Market Report and Forecast 2024-2032

Global Chronic Disease Management Market Outlook

The global chronic disease management market size was valued at USD 7.66 billion in 2023, driven by the increasing prevalence of chronic diseases across the globe. The market size is anticipated to grow at a CAGR of 14.4% during the forecast period of 2024-2032, with values likely to rise from USD 8.77 billion in 2024 and to USD 25.72 billion by 2032.

Global Chronic Disease Management Market Overview

Chronic diseases refer to health conditions that persist over a long period of time. They can last for years or even a lifetime. Chronic diseases are responsible for more than 41 million people every year, almost 75% of the deaths globally. Nearly 17 million people across the world die from chronic diseases before the age of 70 years. Out of these deaths, about 86% of the deaths are registered in low- and middle-income regions. Among these deaths, cardiovascular diseases accounts for the highest number of deaths, almost 17.9 million deaths every year. Cardiovascular diseases are followed by cancers, responsible for over 9.3 million deaths, chronic respiratory diseases accounting for about 4.1 million deaths, and diabetes and kidney related disorders associated with diabetes, accounting for over 2 million deaths annually. These diseases are responsible for more than 80% of premature deaths every year. The key factors contributing to the increasing prevalence of chronic diseases include the rising use of tobacco and alcohol, lack of physical activities, unhealthy diets, and pollution levels.

With the increasing prevalence of chronic disorders, the demand for disease management has also increased. The chronic disease management market demand can be attributed to factors like rising support from the governments, rising investment in research and development of advanced and efficient treatments, and technological advancements, among others.

Increased Support from the Governments

Governments across the world are supporting chronic disease management market growth by introducing various acts and initiatives to increase public awareness. For instance, in March 2023, Chronic Disease Management Act (CDMA) was introduced in the United States Senate. This bill is an expansion on previous versions of CDMA and follows the 2019 guidance issued by the U.S. Department of Treasury to further increase the flexibility of HSA-HDHPs to cover chronic disease services on a pre-deductible basis.

Rise in Research and Development to Propel the Chronic Disease Management Market

The significant increase in the research and development of new drugs for adults suffering from chronic disease have been propelling the market growth. In the past few years, there have been major clinical trials and drug approvals, which has significantly reformed the healthcare sector. Such efforts are anticipated to continue bolstering growth in the coming years as well. For instance, Alzheon, Inc. is conducting a trial on ALZ-801, an amyloid beta-protein inhibitor, is in phase III trial for adult patients suffering from Alzheimer’s disease. It sparks hope for the overall industry as the condition is barely treatable. Notable efforts in the research and development of treatments for such conditions are likely to aid the chronic disease management market demand.

Technological Advancements like Digital Health Tools and Artificial Intelligence to Bring Innovative Changes

The market has been witnessing significant technological advancements over the past few years and artificial intelligence has been a breakthrough for the entire world. The integration of genome, epigenome, microbiome data, among others multi-omics data can prove to be powerful method of studying and analysing these complex diseases and help in developing effective treatment methods.

Constant efforts are being made in the industry to develop innovative technologies, which are likely to contribute significantly to the chronic disease management market share. For instance, in September 2023, the National Institutes of Health (NIH) introduced their BRAIN Initiative. This initiative is aimed at developing data and tools that can help in better understanding of the brain circuit functioning and to lay the foundation that can help diagnose the brain conditions more precisely.

Artificial intelligence, on the other hand, has also found wide applications in the market as it effectively reduces time of development, leading to early diagnosis and early-stage discovery of effective drugs. Constant developments in AI are also likely to aid the market growth in the coming years. In June 2023, the World Economic Forum launched the 2023 report on Technology Pioneers named 'Top 10 Emerging Technologies of 2023’. In this report, significant emphasis was laid on the importance of AI in the future of various industries, including healthcare industry. AI can help in speeding up the process of drug and vaccine approval, along with enhancing the diagnosis and treatment procedures, which will eventually benefit the healthcare industry to a large extent.

Global Chronic Disease Management Market Segmentation

Market Breakup by Type

• Solution

• Services

Market Breakup by Solution Type

• On-Premises Solution

• Cloud-Based Solution

• Web-Based

Market Breakup by Service Type

• Educational Service

• Implementation Service

• Consulting Service

• Others

Market Breakup by Disease Indication

• Cardiovascular Diseases (CVD)

• Diabetes

• Chronic Obstructive Pulmonary Disorders (COPD)

• Arthritis

• Asthma

• Cancer

• Others

Market Breakup by End User

• Healthcare Providers

• Healthcare Payers

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Chronic Disease Management Market Regional Analysis

North America, especially the United States, is likely to lead the global market during the forecast period due to the presence of a geriatric population and the increasing adoption of a sedentary lifestyle leading to chronic diseases. The growth of the market can be attributed to the higher presence of key players in the region. The region has been witnessing rapid developments and is likely to continue dominating the chronic disease management market size.

The number of drug approvals by the US FDA has also increased significantly. For instance, in September 2023, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced that the US FDA approved Jardiance® (empagliflozin) 10 mg tablets. These tablets will have wide application in the treatment of chronic kidney disorders.

Global Chronic Disease Management Market: Competitor Landscape

News and Development

In March 2023, Royal Philips (NYSE: PHG) announced the launch of Philips Virtual Care Management. It would offer a portfolio of various services and solutions that will make the process of health systems, providers, employers, and payers much easier. It would also help the physicians connect with the patients virtually from anywhere in the world. The system would significantly reduce the pressure on hospital and staff by reducing the number of emergency visits since they can be consulted virtually. It would be a cost-efficient alternative for the patients, therefore likely to witness significant demand in the coming years.

In October 2023, WellSky acquired Corridor, which is an end-to-end enable services platform, known to deal with pots-acute challenges faced in the industry. Wellsky acquired the latter from HealthEdge Investment Partners, which is a private equity firm working in the healthcare industry. With this acquisition, WellSky will be able to expand its footprint in medical coding as well as and revenue cycle management (RCM). The company will then be able to offer better services to the patients.

The key features of the chronic disease management market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

The major companies in the market are as follows:

• WellSky

• ZeOmega

• Health Catalyst

• Cedar Gate Technologies

• Cognizant

• Pegasystems Inc.

• Epic Systems Corporation

• Hinduja Global Solutions Ltd.

• NXGN Management, LLC

• MINES & Associates, Inc.

• Koninklijke Philips N.V

• Vivify Health, Inc

• Allscripts Healthcare, LLC

• Casenet, LLC

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report